HONG KONG – The speed of approvals of biotechnology products in China remains a bone of contention for trade authorities in the U.S., even though "progress was made on some meaningful issues" in terms of market access within the second largest economy in the world in 2014. Trade authorities in the U.S. also have concerns surrounding patents and technology transfers for the pharmaceutical industry.